Which has stronger valuation & earnings, NCEL or CRDF?

NLS Pharmaceutics has higher earnings, but lower revenue than Cardiff Oncology. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NLS Pharmaceutics N/A N/A -$8.30M N/A N/A Cardiff Oncology $590K 116.04 -$45.85M -$0.60 N/A

Which has preferable valuation and earnings, NCEL or CTOR?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NLS Pharmaceutics N/A N/A -$8.30M N/A N/A Citius Oncology N/A N/A -$24.76M -$0.47 N/A

Is NCEL or CTOR more profitable?

NLS Pharmaceutics' return on equity of 0.00% beat Citius Oncology's return on equity. Company Net Margins Return on Equity Return on Assets NLS Pharmaceutics N/A N/A N/A Citius Oncology N/A -102.98% -43.49%

Which has better earnings and valuation, PMVP or NCEL?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PMV Pharmaceuticals N/A N/A -$77.74M -$1.42 N/A NLS Pharmaceutics N/A N/A -$8.30M N/A N/A

Is PMVP or NCEL more profitable?

NLS Pharmaceutics' return on equity of 0.00% beat PMV Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets PMV Pharmaceuticals N/A -78.11% -70.13% NLS Pharmaceutics N/A N/A N/A

Which has preferable earnings & valuation, NCEL or RNTX?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NLS Pharmaceutics N/A N/A -$8.30M N/A N/A Rein Therapeutics N/A N/A -$49.87M -$1.72 N/A

Is NCEL or RNTX more profitable?

Company Net Margins Return on Equity Return on Assets NLS Pharmaceutics N/A N/A N/A Rein Therapeutics N/A N/A -63.69%

Which has stronger valuation & earnings, NCEL or IMA?

NLS Pharmaceutics has higher earnings, but lower revenue than ImageneBio. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NLS Pharmaceutics N/A N/A -$8.30M N/A N/A ImageneBio $800K 78.17 -$45.35M -$4.58 N/A

Is NCEL or IMA more profitable?

NLS Pharmaceutics' return on equity of 0.00% beat ImageneBio's return on equity. Company Net Margins Return on Equity Return on Assets NLS Pharmaceutics N/A N/A N/A ImageneBio N/A -38.99% -34.84%

NLS Pharmaceutics (NCEL) Competitors

$3.26 0.00 (0.00%)

As of 08/21/2026 01:20 PM Eastern

Compare

NCEL vs. CRDF, CTOR, PMVP, RNTX, and IMA

Should you buy NLS Pharmaceutics stock or one of its competitors? NLS Pharmaceutics's main competitors and comparable companies include Cardiff Oncology (CRDF), Citius Oncology (CTOR), PMV Pharmaceuticals (PMVP), Rein Therapeutics (RNTX), and ImageneBio (IMA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does NLS Pharmaceutics compare to Cardiff Oncology?

NLS Pharmaceutics (NASDAQ:NCEL) and Cardiff Oncology (NASDAQ:CRDF) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, risk, dividends, valuation, media sentiment, analyst recommendations, earnings and institutional ownership.

16.3% of Cardiff Oncology shares are held by institutional investors. 16.4% of NLS Pharmaceutics shares are held by insiders. Comparatively, 8.5% of Cardiff Oncology shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

NLS Pharmaceutics presently has a consensus price target of $23.00, suggesting a potential upside of 605.52%. Cardiff Oncology has a consensus price target of $7.50, suggesting a potential upside of 752.18%. Given Cardiff Oncology's stronger consensus rating and higher probable upside, analysts plainly believe Cardiff Oncology is more favorable than NLS Pharmaceutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NLS Pharmaceutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Cardiff Oncology	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14

In the previous week, Cardiff Oncology had 8 more articles in the media than NLS Pharmaceutics. MarketBeat recorded 8 mentions for Cardiff Oncology and 0 mentions for NLS Pharmaceutics. Cardiff Oncology's average media sentiment score of 0.82 beat NLS Pharmaceutics' score of 0.00 indicating that Cardiff Oncology is being referred to more favorably in the news media.

Company	Overall Sentiment
NLS Pharmaceutics	Neutral
Cardiff Oncology	Positive

NLS Pharmaceutics has a net margin of 0.00% compared to Cardiff Oncology's net margin of -7,885.43%. NLS Pharmaceutics' return on equity of 0.00% beat Cardiff Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NLS Pharmaceutics	N/A	N/A	N/A
Cardiff Oncology	-7,885.43%	-103.10%	-75.52%

NLS Pharmaceutics has higher earnings, but lower revenue than Cardiff Oncology.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NLS Pharmaceutics	N/A	N/A	-$8.30M	N/A	N/A
Cardiff Oncology	$590K	116.04	-$45.85M	-$0.60	N/A

NLS Pharmaceutics has a beta of 0.94, indicating that its share price is 6% less volatile than the broader market. Comparatively, Cardiff Oncology has a beta of 1.5, indicating that its share price is 50% more volatile than the broader market.

Summary

Cardiff Oncology beats NLS Pharmaceutics on 8 of the 13 factors compared between the two stocks.

How does NLS Pharmaceutics compare to Citius Oncology?

NLS Pharmaceutics (NASDAQ:NCEL) and Citius Oncology (NASDAQ:CTOR) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, dividends and risk.

NLS Pharmaceutics currently has a consensus target price of $23.00, suggesting a potential upside of 605.52%. Citius Oncology has a consensus target price of $6.00, suggesting a potential upside of 706.67%. Given Citius Oncology's stronger consensus rating and higher probable upside, analysts plainly believe Citius Oncology is more favorable than NLS Pharmaceutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NLS Pharmaceutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Citius Oncology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

70.5% of Citius Oncology shares are held by institutional investors. 16.4% of NLS Pharmaceutics shares are held by insiders. Comparatively, 9.8% of Citius Oncology shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Citius Oncology had 1 more articles in the media than NLS Pharmaceutics. MarketBeat recorded 1 mentions for Citius Oncology and 0 mentions for NLS Pharmaceutics. Citius Oncology's average media sentiment score of 0.15 beat NLS Pharmaceutics' score of 0.00 indicating that Citius Oncology is being referred to more favorably in the news media.

Company	Overall Sentiment
NLS Pharmaceutics	Neutral
Citius Oncology	Neutral

NLS Pharmaceutics has a beta of 0.94, indicating that its share price is 6% less volatile than the broader market. Comparatively, Citius Oncology has a beta of 3.48, indicating that its share price is 248% more volatile than the broader market.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NLS Pharmaceutics	N/A	N/A	-$8.30M	N/A	N/A
Citius Oncology	N/A	N/A	-$24.76M	-$0.47	N/A

NLS Pharmaceutics' return on equity of 0.00% beat Citius Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NLS Pharmaceutics	N/A	N/A	N/A
Citius Oncology	N/A	-102.98%	-43.49%

Summary

Citius Oncology beats NLS Pharmaceutics on 7 of the 11 factors compared between the two stocks.

How does NLS Pharmaceutics compare to PMV Pharmaceuticals?

PMV Pharmaceuticals (NASDAQ:PMVP) and NLS Pharmaceutics (NASDAQ:NCEL) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, dividends, risk, profitability, earnings and media sentiment.

In the previous week, PMV Pharmaceuticals' average media sentiment score of 1.00 beat NLS Pharmaceutics' score of 0.00 indicating that PMV Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
PMV Pharmaceuticals	Positive
NLS Pharmaceutics	Neutral

90.2% of PMV Pharmaceuticals shares are owned by institutional investors. 10.2% of PMV Pharmaceuticals shares are owned by insiders. Comparatively, 16.4% of NLS Pharmaceutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

PMV Pharmaceuticals currently has a consensus price target of $4.00, suggesting a potential upside of 200.75%. NLS Pharmaceutics has a consensus price target of $23.00, suggesting a potential upside of 605.52%. Given NLS Pharmaceutics' higher possible upside, analysts plainly believe NLS Pharmaceutics is more favorable than PMV Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PMV Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
NLS Pharmaceutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PMV Pharmaceuticals	N/A	N/A	-$77.74M	-$1.42	N/A
NLS Pharmaceutics	N/A	N/A	-$8.30M	N/A	N/A

NLS Pharmaceutics' return on equity of 0.00% beat PMV Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PMV Pharmaceuticals	N/A	-78.11%	-70.13%
NLS Pharmaceutics	N/A	N/A	N/A

PMV Pharmaceuticals has a beta of 1.34, meaning that its share price is 34% more volatile than the broader market. Comparatively, NLS Pharmaceutics has a beta of 0.94, meaning that its share price is 6% less volatile than the broader market.

Summary

PMV Pharmaceuticals beats NLS Pharmaceutics on 6 of the 11 factors compared between the two stocks.

How does NLS Pharmaceutics compare to Rein Therapeutics?

NLS Pharmaceutics (NASDAQ:NCEL) and Rein Therapeutics (NASDAQ:RNTX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, media sentiment, risk, valuation, dividends, analyst recommendations, earnings and institutional ownership.

In the previous week, Rein Therapeutics had 14 more articles in the media than NLS Pharmaceutics. MarketBeat recorded 14 mentions for Rein Therapeutics and 0 mentions for NLS Pharmaceutics. Rein Therapeutics' average media sentiment score of 0.19 beat NLS Pharmaceutics' score of 0.00 indicating that Rein Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
NLS Pharmaceutics	Neutral
Rein Therapeutics	Neutral

NLS Pharmaceutics has a beta of 0.94, suggesting that its stock price is 6% less volatile than the broader market. Comparatively, Rein Therapeutics has a beta of 1.39, suggesting that its stock price is 39% more volatile than the broader market.

Company	Net Margins	Return on Equity	Return on Assets
NLS Pharmaceutics	N/A	N/A	N/A
Rein Therapeutics	N/A	N/A	-63.69%

NLS Pharmaceutics currently has a consensus target price of $23.00, indicating a potential upside of 605.52%. Rein Therapeutics has a consensus target price of $6.00, indicating a potential upside of 633.50%. Given Rein Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Rein Therapeutics is more favorable than NLS Pharmaceutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NLS Pharmaceutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Rein Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

90.9% of Rein Therapeutics shares are held by institutional investors. 16.4% of NLS Pharmaceutics shares are held by insiders. Comparatively, 1.5% of Rein Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NLS Pharmaceutics	N/A	N/A	-$8.30M	N/A	N/A
Rein Therapeutics	N/A	N/A	-$49.87M	-$1.72	N/A

Summary

Rein Therapeutics beats NLS Pharmaceutics on 7 of the 10 factors compared between the two stocks.

How does NLS Pharmaceutics compare to ImageneBio?

NLS Pharmaceutics (NASDAQ:NCEL) and ImageneBio (NASDAQ:IMA) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their risk, valuation, media sentiment, analyst recommendations, dividends, earnings, institutional ownership and profitability.

In the previous week, ImageneBio had 8 more articles in the media than NLS Pharmaceutics. MarketBeat recorded 8 mentions for ImageneBio and 0 mentions for NLS Pharmaceutics. ImageneBio's average media sentiment score of 0.80 beat NLS Pharmaceutics' score of 0.00 indicating that ImageneBio is being referred to more favorably in the news media.

Company	Overall Sentiment
NLS Pharmaceutics	Neutral
ImageneBio	Positive

NLS Pharmaceutics has higher earnings, but lower revenue than ImageneBio.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NLS Pharmaceutics	N/A	N/A	-$8.30M	N/A	N/A
ImageneBio	$800K	78.17	-$45.35M	-$4.58	N/A

NLS Pharmaceutics' return on equity of 0.00% beat ImageneBio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NLS Pharmaceutics	N/A	N/A	N/A
ImageneBio	N/A	-38.99%	-34.84%

75.0% of ImageneBio shares are held by institutional investors. 16.4% of NLS Pharmaceutics shares are held by company insiders. Comparatively, 2.2% of ImageneBio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

NLS Pharmaceutics has a beta of 0.94, suggesting that its share price is 6% less volatile than the broader market. Comparatively, ImageneBio has a beta of 0.76, suggesting that its share price is 24% less volatile than the broader market.

NLS Pharmaceutics presently has a consensus price target of $23.00, indicating a potential upside of 605.52%. ImageneBio has a consensus price target of $29.00, indicating a potential upside of 426.32%. Given NLS Pharmaceutics' higher probable upside, analysts clearly believe NLS Pharmaceutics is more favorable than ImageneBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NLS Pharmaceutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
ImageneBio	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.20

Summary

NLS Pharmaceutics and ImageneBio tied by winning 6 of the 12 factors compared between the two stocks.

Get NLS Pharmaceutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NCEL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NCEL vs. The Competition

Export

Metric	NLS Pharmaceutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$18.84M	$4.00B	$7.32B	$12.82B
Dividend Yield	N/A	3.64%	2.54%	10.78%
P/E Ratio	N/A	11.68	272.91	24.33
Price / Sales	N/A	1,377.87	639.20	97.25
Price / Cash	N/A	44.94	29.03	36.90
Price / Book	2.05	17.70	11.38	6.42
Net Income	-$8.30M	-$22.72M	$3.47B	$348.89M
7 Day Performance	N/A	2.73%	2.16%	0.51%
1 Month Performance	-13.30%	9.63%	7.59%	4.84%
1 Year Performance	-87.60%	54.98%	25.16%	17.04%

NLS Pharmaceutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NCEL NLS Pharmaceutics	2.4332 of 5 stars	$3.26 flat	$23.00 +605.5%	-87.6%	$18.84M	N/A	N/A	6
CRDF Cardiff Oncology	3.4337 of 5 stars	$0.90 +1.3%	$7.50 +735.2%	-62.1%	$69.39M	$590K	N/A	20	Gap Up
CTOR Citius Oncology	1.7878 of 5 stars	$0.75 +6.1%	$6.00 +704.3%	-57.5%	$69.36M	N/A	N/A	N/A	Gap Down
PMVP PMV Pharmaceuticals	2.9947 of 5 stars	$1.27 +2.0%	$4.00 +216.2%	-10.1%	$67.20M	N/A	N/A	50	Positive News
RNTX Rein Therapeutics	3.5725 of 5 stars	$0.79 +1.9%	$6.00 +664.3%	-35.6%	$67.15M	N/A	N/A	9	Analyst Downgrade Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NCEL) was last updated on 8/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

NLS Pharmaceutics (NCEL) Competitors

NCEL vs. CRDF, CTOR, PMVP, RNTX, and IMA

How does NLS Pharmaceutics compare to Cardiff Oncology?

Summary

How does NLS Pharmaceutics compare to Citius Oncology?

Summary

How does NLS Pharmaceutics compare to PMV Pharmaceuticals?

Summary

How does NLS Pharmaceutics compare to Rein Therapeutics?

Summary

How does NLS Pharmaceutics compare to ImageneBio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NCEL vs. The Competition

NLS Pharmaceutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

NLS Pharmaceutics (NCEL) Competitors

NCEL vs. CRDF, CTOR, PMVP, RNTX, and IMA

How does NLS Pharmaceutics compare to Cardiff Oncology?

Do insiders and institutionals hold more shares of NCEL or CRDF?

Do analysts recommend NCEL or CRDF?

Does the media favor NCEL or CRDF?

Is NCEL or CRDF more profitable?

Which has stronger valuation & earnings, NCEL or CRDF?

Which has more risk and volatility, NCEL or CRDF?

Summary

How does NLS Pharmaceutics compare to Citius Oncology?

Do analysts rate NCEL or CTOR?

Do insiders & institutionals have more ownership in NCEL or CTOR?

Does the media refer more to NCEL or CTOR?

Which has more volatility & risk, NCEL or CTOR?

Which has preferable valuation and earnings, NCEL or CTOR?

Is NCEL or CTOR more profitable?

Summary

How does NLS Pharmaceutics compare to PMV Pharmaceuticals?

Does the media prefer PMVP or NCEL?

Do insiders and institutionals have more ownership in PMVP or NCEL?

Do analysts prefer PMVP or NCEL?

Which has better earnings and valuation, PMVP or NCEL?

Is PMVP or NCEL more profitable?

Which has more volatility & risk, PMVP or NCEL?

Summary

How does NLS Pharmaceutics compare to Rein Therapeutics?

Does the media refer more to NCEL or RNTX?

Which has more risk and volatility, NCEL or RNTX?

Is NCEL or RNTX more profitable?

Do analysts prefer NCEL or RNTX?

Do institutionals & insiders hold more shares of NCEL or RNTX?

Which has preferable earnings & valuation, NCEL or RNTX?

Summary

How does NLS Pharmaceutics compare to ImageneBio?

Does the media refer more to NCEL or IMA?

Which has stronger valuation & earnings, NCEL or IMA?

Is NCEL or IMA more profitable?

Do insiders & institutionals hold more shares of NCEL or IMA?

Which has more volatility and risk, NCEL or IMA?

Do analysts prefer NCEL or IMA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NCEL vs. The Competition

NLS Pharmaceutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools